在治疗乙型肝炎病毒相关性肝细胞癌时，继续治疗与起始抗病毒治疗的疗效相当。
Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma.
机构信息
Division of Gastroenterology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
出版信息
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1877-1880.e3. doi: 10.1016/j.cgh.2022.02.014. Epub 2022 Feb 15.
Suppression of hepatitis B virus (HBV) replication with antiviral therapy (AVT) using nucleos(t)ide analogs reduces the risk of hepatocellular carcinoma (HCC) recurrence and prolongs survival after curative treatment. Studies of the association between timing of AVT initiation and prognosis of patients with HCC receiving curative treatment are scarce. In the present study, we compared the therapeutic benefit of AVT, commenced before vs after curative treatment of HBV-related HCC, on long-term prognosis.
抗病毒治疗（AVT）抑制乙型肝炎病毒（HBV）复制，使用核苷（酸）类似物可降低肝癌（HCC）复发的风险，并延长根治性治疗后的生存时间。关于开始 AVT 的时间与接受根治性治疗的 HCC 患者预后之间的关联的研究很少。在本研究中，我们比较了在 HBV 相关 HCC 根治性治疗之前和之后开始 AVT 对长期预后的治疗益处。
Zotero 插件